Compare Stocks: VTVT, ASMB, OVID, and CTNM

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ASMB Assembly Biosciences	$23.21 -1.2%	$29.19	$21.80 ▼ $39.71	$472.66M	1.13	186,665 shs	105,202 shs
CTNM Contineum Therapeutics	$12.76 -4.9%	$14.99	$8.60 ▼ $17.78	$480.03M	0.75	358,769 shs	343,822 shs
OVID Ovid Therapeutics	$2.50 +0.2%	$2.65	$1.18 ▼ $3.11	$489.23M	0.24	2.33 million shs	665,295 shs
VTVT vTv Therapeutics	$31.76 +3.0%	$32.13	$19.50 ▼ $44.00	$125.12M	0.29	54,834 shs	21,955 shs

7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ASMB Assembly Biosciences	+0.04%	-2.00%	-30.15%	-15.32%	-8.24%
CTNM Contineum Therapeutics	+16.70%	+7.27%	-17.36%	-11.13%	+14.21%
OVID Ovid Therapeutics	-1.97%	-3.11%	-6.74%	-7.43%	+91.54%
VTVT vTv Therapeutics	+2.80%	+0.85%	-3.63%	-12.88%	+31.51%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ASMB Assembly Biosciences	$23.21 -1.2%	$29.19	$21.80 ▼ $39.71	$472.66M	1.13	186,665 shs	105,202 shs
CTNM Contineum Therapeutics	$12.76 -4.9%	$14.99	$8.60 ▼ $17.78	$480.03M	0.75	358,769 shs	343,822 shs
OVID Ovid Therapeutics	$2.50 +0.2%	$2.65	$1.18 ▼ $3.11	$489.23M	0.24	2.33 million shs	665,295 shs
VTVT vTv Therapeutics	$31.76 +3.0%	$32.13	$19.50 ▼ $44.00	$125.12M	0.29	54,834 shs	21,955 shs

7 Stocks to Buy Before the Robotics Revolution

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ASMB Assembly Biosciences	+0.04%	-2.00%	-30.15%	-15.32%	-8.24%
CTNM Contineum Therapeutics	+16.70%	+7.27%	-17.36%	-11.13%	+14.21%
OVID Ovid Therapeutics	-1.97%	-3.11%	-6.74%	-7.43%	+91.54%
VTVT vTv Therapeutics	+2.80%	+0.85%	-3.63%	-12.88%	+31.51%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ASMB Assembly Biosciences	2.83	Moderate Buy	$47.50	104.62% Upside
CTNM Contineum Therapeutics	2.50	Moderate Buy	$22.17	73.72% Upside
OVID Ovid Therapeutics	2.90	Moderate Buy	$6.00	140.48% Upside
VTVT vTv Therapeutics	2.78	Moderate Buy	$55.83	75.83% Upside

Current Analyst Ratings Breakdown

Latest VTVT, ASMB, OVID, and CTNM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/30/2026	CTNM Contineum Therapeutics	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$28.00
9/28/2026	CTNM Contineum Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Equal Weight	$18.00 ➝ $17.00
9/15/2026	CTNM Contineum Therapeutics	JonesTrading Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$26.00 ➝ $24.00
9/15/2026	CTNM Contineum Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$20.00 ➝ $19.00
9/11/2026	OVID Ovid Therapeutics	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
9/11/2026	OVID Ovid Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$4.00 ➝ $5.00
9/7/2026	VTVT vTv Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
9/3/2026	OVID Ovid Therapeutics	Roth Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$8.00
9/2/2026	VTVT vTv Therapeutics	Lifesci Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
9/1/2026	ASMB Assembly Biosciences	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$53.00
9/1/2026	ASMB Assembly Biosciences	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$52.00

(Data available from 10/1/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ASMB Assembly Biosciences	$72.30M	6.54	N/A	N/A	$13.04 per share	1.78
CTNM Contineum Therapeutics	$50M	9.60	N/A	N/A	$6.99 per share	1.83
OVID Ovid Therapeutics	$7.25M	67.21	N/A	N/A	$1.00 per share	2.50
VTVT vTv Therapeutics	$1.02M	122.66	N/A	N/A	$16.36 per share	1.94

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ASMB Assembly Biosciences	-$6.12M	$1.02	22.76	464.28	N/A	-0.06%	-0.02%	-0.02%	11/9/2026 (Estimated)
CTNM Contineum Therapeutics	-$59.98M	-$1.73	N/A	N/A	N/A	N/A	-24.73%	-23.51%	10/29/2026 (Estimated)
OVID Ovid Therapeutics	-$17.41M	-$0.31	N/A	N/A	N/A	-240.11%	-23.64%	-20.52%	11/11/2026 (Estimated)
VTVT vTv Therapeutics	-$26.97M	-$1.06	N/A	N/A	N/A	N/A	-6.27%	-5.06%	11/5/2026 (Estimated)

Latest VTVT, ASMB, OVID, and CTNM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
10/29/2026	Q3 2026	CTNM Contineum Therapeutics	-$0.45	N/A	N/A	N/A	$5.65 million	N/A
8/13/2026	Q2 2026	ASMB Assembly Biosciences	-$0.7242	-$0.20	+$0.5242	-$0.20	$8.60 million	$13.37 million
8/13/2026	Q2 2026	OVID Ovid Therapeutics	-$0.1150	-$0.08	+$0.0350	-$0.08	$0.02 million	$0.73 million
8/6/2026	Q2 2026	VTVT vTv Therapeutics	-$0.97	-$1.05	-$0.08	-$1.05	$0.33 million	N/A
7/30/2026	Q2 2026	CTNM Contineum Therapeutics	-$0.4488	-$0.40	+$0.0488	-$0.40	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ASMB Assembly Biosciences	N/A	N/A	N/A	N/A	N/A
CTNM Contineum Therapeutics	N/A	N/A	N/A	N/A	N/A
OVID Ovid Therapeutics	N/A	N/A	N/A	N/A	N/A
VTVT vTv Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ASMB Assembly Biosciences	N/A	13.99	13.99
CTNM Contineum Therapeutics	N/A	37.17	37.17
OVID Ovid Therapeutics	0.05	12.39	12.39
VTVT vTv Therapeutics	N/A	12.48	12.48

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ASMB Assembly Biosciences	19.92%
CTNM Contineum Therapeutics	N/A
OVID Ovid Therapeutics	72.24%
VTVT vTv Therapeutics	17.51%

Insider Ownership

Company	Insider Ownership
ASMB Assembly Biosciences	3.50%
CTNM Contineum Therapeutics	7.90%
OVID Ovid Therapeutics	7.00%
VTVT vTv Therapeutics	5.99%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ASMB Assembly Biosciences	73	20.36 million	19.65 million	Optionable
CTNM Contineum Therapeutics	51	37.62 million	34.65 million	N/A
OVID Ovid Therapeutics	23	195.30 million	181.63 million	Optionable
VTVT vTv Therapeutics	26	3.94 million	3.70 million	Not Optionable

VTVT, ASMB, OVID, and CTNM Headlines

Recent News About These Companies

Head-To-Head Survey: Theravance Biopharma (NASDAQ:TBPH) vs. vTv Therapeutics (NASDAQ:VTVT)

September 28 at 6:14 AM | americanbankingnews.com

Head to Head Contrast: Enanta Pharmaceuticals (NASDAQ:ENTA) versus vTv Therapeutics (NASDAQ:VTVT)

September 28 at 4:28 AM | americanbankingnews.com

vTv Therapeutics (NASDAQ:VTVT) Stock Price Crosses Below 50 Day Moving Average - Here's What Happened

September 23, 2026 | marketbeat.com

vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - September 15, 2026

September 15, 2026 | biospace.comB

vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

September 15, 2026 | globenewswire.com

vTv Therapeutics Inc. (NASDAQ:VTVT) Receives Consensus Recommendation of "Moderate Buy" from Analysts

September 12, 2026 | marketbeat.com

vTv Therapeutics (NASDAQ:VTVT) Raised to Hold at Zacks Research

September 9, 2026 | marketbeat.com

Lifesci Capital Upgrades vTv Therapeutics (NASDAQ:VTVT) to Strong-Buy

September 4, 2026 | marketbeat.com

Analysts Conflicted on These Healthcare Names: Kymera Therapeutics (KYMR) and vTv Therapeutics (VTVT)

September 3, 2026 | theglobeandmail.com

vTv Therapeutics to Participate in September Investor Conferences

September 2, 2026 | globenewswire.com

vTv Therapeutics (NASDAQ:VTVT) Stock Price Passes Below 50-Day Moving Average - Should You Sell?

September 2, 2026 | marketbeat.com

vTv Therapeutics Inc. Cl A

August 30, 2026 | barrons.com

vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

August 19, 2026 | globenewswire.com

vTv Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

August 7, 2026 | markets.businessinsider.com

vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

July 28, 2026 | globenewswire.com

vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

July 2, 2026 | globenewswire.com

vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

June 2, 2026 | globenewswire.com

vTv Therapeutics Inc. (NASDAQ:VTVT) Just Beat Earnings: Here's What Analysts Think Will Happen Next

May 17, 2026 | finance.yahoo.com

Why vTv Therapeutics Inc.’s (VTVT) Stock Is Down 8.13%

May 16, 2026 | aaii.comA

vTv Therapeutics (VTVT) is on the Move, Here's Why the Trend Could be Sustainable

May 15, 2026 | zacks.com

vTv Therapeutics Expands At-The-Market Share Program Capacity

May 13, 2026 | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

VTVT, ASMB, OVID, and CTNM Company Descriptions

Assembly Biosciences NASDAQ:ASMB

$23.21 -0.28 (-1.17%)

As of 01:48 PM Eastern

Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial. The company also develops ABI-4334, a next-generation capsid assembly modulator, which is in Phase 1b clinical trial for the treatment of hepatitis B virus (HBV). In addition, it develops an oral non-nucleoside polymerase inhibitor targeting transplant-related herpesviruses; and a small molecule interferon-a receptor agonist targeting HBV and HDV. The company has collaboration agreements with Gilead Sciences, Inc. and BeiGene, Ltd. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.

Contineum Therapeutics NASDAQ:CTNM

$12.76 -0.66 (-4.92%)

As of 01:48 PM Eastern

Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. The company was incorporated in 2009 and is headquartered in San Diego, California.

Ovid Therapeutics NASDAQ:OVID

$2.50 +0.01 (+0.20%)

As of 01:49 PM Eastern

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.

vTv Therapeutics NASDAQ:VTVT

$31.76 +0.92 (+2.97%)

As of 01:48 PM Eastern

vTv Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes. It is also developing HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 inhibitor, which is in Phase III trial for the treatment of psoriasis, COPD, and atopic dermatitis, as well as TTP-RA, a RAGE antagonist for type 1 diabetes prevention. In addition, the company's other programs include HPP3033, a non-electrophilic therapeutic approach to activating the nuclear factor erythroid 2related factor 2 (Nrf2) pathway for the treatment of chronic diseases associated with oxidative stress; and Azeliragon, a RAGE antagonist for inflammatory lung diseases, including severe COVID-19, as well as for glioblastoma, other cancers, and cancer treatment-related conditions. vTv Therapeutics Inc. has license agreements with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593 for therapeutic, prophylactic, and diagnostic application; and Anteris Bio, Inc. to develop and commercialize HPP971, a Nrf2 activator, as well as with Cantex Pharmaceuticals, Inc.; Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.; Newsoara Biopharma Co., Ltd.; JDRF International; and Novo Nordisk A/S. The company was incorporated in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Incorporated.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest VTVT, ASMB, OVID, and CTNM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest VTVT, ASMB, OVID, and CTNM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

VTVT, ASMB, OVID, and CTNM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

VTVT, ASMB, OVID, and CTNM Company Descriptions

Assembly Biosciences NASDAQ:ASMB

Contineum Therapeutics NASDAQ:CTNM

Ovid Therapeutics NASDAQ:OVID

vTv Therapeutics NASDAQ:VTVT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest VTVT, ASMB, OVID, and CTNM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest VTVT, ASMB, OVID, and CTNM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

VTVT, ASMB, OVID, and CTNM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

VTVT, ASMB, OVID, and CTNM Company Descriptions

Assembly Biosciences NASDAQ:ASMB

Contineum Therapeutics NASDAQ:CTNM

Ovid Therapeutics NASDAQ:OVID

vTv Therapeutics NASDAQ:VTVT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools